AcuCort’s first drug Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. Zeqmelit® is approved for the treatment of acute and severe allergic reactions, croup in children, nausea and vomiting during chemotherapy and for patients with COVID-19 with breathing difficulties and need for oxygen therapy.
The goal is to commercialize Zeqmelit® globally, that is, in the EU, the US and selected key markets. The company’s strategy is to attract partners with regional or global market presence as well as expertise and resources to quickly launch after regulatory approval. Dialogues with potential partners in prioritized markets are ongoing.